SK Biopharmaceuticals Co., Ltd. (326030.KS) on Thursday reported a significant jump in first-quarter earnings, mainly driven by strong revenue growth.
Net income from continuing operation before income tax surged 391.6% to 99.978 billion won from 20.337 billion won in the prior-year quarter.
Operating profit jumped 249.7% to 89.768 billion won from 25.672 billion won a year earlier.
Net income attributable to shareholders of the parent company climbed 351.2% to 105.162 billion won from 23.305 billion won in the corresponding quarter last year.
Revenue rose 57.8% to 227.886 billion won from 144.377 billion won a year earlier.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.